Brief: Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Positive Results From Solid Tumor Study Of Lymphir In Combination With Checkpoint Inhibitor
31/10/2023 12:50
Oct 31 (Reuters) - Citius Pharmaceuticals Inc CTXR.O :
* CITIUS PHARMACEUTICALS ANNOUNCES PUBLICATION IN FRONTIERS
OF
IMMUNOLOGY OF POSITIVE RESULTS FROM SOLID TUMOR STUDY OF
LYMPHIR™ IN COMBINATION WITH CHECKPOINT INHIBITOR
Source text for Eikon: ID:nPn2LgrSva
Further company coverage: CTXR.O
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules